Wordt geladen...
Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus Infection in a Large Integrated Care Setting
BACKGROUND: In 2011, the FDA approved telaprevir (TVR) and boceprevir (BOC) for use with pegylated-interferon and ribavirin to treat hepatitis C virus (HCV) genotype 1. We aimed to evaluate the real-world application, tolerability, and effectiveness of TVR and BOC-based HCV treatment in a large inte...
Bewaard in:
| Gepubliceerd in: | Dig Dis Sci |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4237658/ https://ncbi.nlm.nih.gov/pubmed/25102983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-014-3294-0 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|